Based on the key indicators related to Dianthus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Dianthus Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. As of now, Dianthus Therapeutics' Accumulated Other Comprehensive Income is decreasing as compared to previous years. The Dianthus Therapeutics' current Non Currrent Assets Other is estimated to increase to about 1.1 M, while Total Assets are projected to decrease to under 112.5 M. Key indicators impacting Dianthus Therapeutics' financial strength include:
Investors should never underestimate Dianthus Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Dianthus Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Dianthus Therapeutics.
Net Income
(45.73 Million)
Dianthus
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Accumulated Other Comprehensive Income
Common Stock
Non Currrent Assets Other
Other Assets
Short Term Investments
Non Current Liabilities Total
Depreciation And Amortization
Interest Expense
Selling General Administrative
Selling And Marketing Expenses
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Probability Of Bankruptcy
Understanding current and past Dianthus Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Dianthus Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Dianthus Therapeutics' assets may result in an increase in income on the income statement.
Comparative valuation techniques use various fundamental indicators to help in determining Dianthus Therapeutics's current stock value. Our valuation model uses many indicators to compare Dianthus Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dianthus Therapeutics competition to find correlations between indicators driving Dianthus Therapeutics's intrinsic value. More Info.
Dianthus Therapeutics is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . As of now, Dianthus Therapeutics' Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dianthus Therapeutics' earnings, one of the primary drivers of an investment's value.
Dianthus Therapeutics Systematic Risk
Dianthus Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Dianthus Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Dianthus Therapeutics correlated with the market. If Beta is less than 0 Dianthus Therapeutics generally moves in the opposite direction as compared to the market. If Dianthus Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Dianthus Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Dianthus Therapeutics is generally in the same direction as the market. If Beta > 1 Dianthus Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Dianthus Therapeutics Thematic Clasifications
Dianthus Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Dianthus Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Dianthus Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Dianthus Therapeutics growth as a starting point in their analysis.
Dianthus Therapeutics November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Dianthus Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Dianthus Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Dianthus Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Dianthus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Dianthus Therapeutics's daily price indicators and compare them against related drivers.
When running Dianthus Therapeutics' price analysis, check to measure Dianthus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dianthus Therapeutics is operating at the current time. Most of Dianthus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dianthus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dianthus Therapeutics' price. Additionally, you may evaluate how the addition of Dianthus Therapeutics to your portfolios can decrease your overall portfolio volatility.